Sapience Reports Positive Glioblastoma Trial Data
TARRYTOWN, N.Y., May 21, 2026 Sapience Therapeutics has announced encouraging updated clinical data from its ongoing Phase 2 trial...
glioblastoma
Advertisement
Diakonos Gains FDA Fast Track for DOC1021 Melanoma
HOUSTON, May 6, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, has announced that...
Diakonos Oncology Reports Phase 1 DOC1021 Survival Data
Houston, USA | May 1, 2026 Diakonos Oncology has reported positive Phase 1 clinical data for its investigational DOC1021...
EnGeneIC Doses First Patient in GBM EDV Therapy Trial
SYDNEY, AUSTRALIA, May 01, 2026 EnGeneIC has announced a critical clinical milestone with the first patient dosed in its...
Telix Doses First Patient in Phase 3 Glioblastoma Trial
Melbourne, Australia & Indianapolis, Indiana, U.S. | April 15, 2026 Telix Pharmaceuticals has announced a major clinical milestone with...
Advertisements
Alpheus Medical Starts Phase 2b Trial in Glioblastoma
CHANHASSEN, Minnesota, April 9, 2026 Alpheus Medical, Inc. has announced the initiation of its Phase 2b randomized clinical trial...
FDA Clears Allogeneic CAR-T MT027 for Phase II Glioblastoma
December 21, 2025 | Beijing, China — T-MAXIMUM Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has...
IN8bio Reports Strong Q3 Progress in Gamma-Delta T Cell R&D
NEW YORK, November 6, 2025 — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell...
Glioblastoma Alters Skull Marrow: New Systemic Insight
BRONX, NY, Oct. 3, 2025 — Researchers at Montefiore Einstein and Albert Einstein College of Medicine reveal that glioblastoma...
Advertisement
